Electrical activity and fatigue of respiratory and locomotor muscles in obstructive respiratory diseases during field walking test

Jéssica D. Cavalcanti 1 ☯, Guilherme Augusto F. Fregonezi 1 ☯, Antonio J. Sarmento 1 ☯, Thiago Bezerra 1 ☯, Lucien P. Gualdi 2 ☯, Francesca Pennati 3 ☯, Andrea Aliverti 3 ☯, Vanessa R. Resqueti 1 ☯ *

1 Departamento de Fisioterapia, Laboratório PneumoCardioVascular—Hospital Universitário Onofre Lopes / Empresa Brasileira de Serviços Hospitalares & Laboratório de Inovação Tecnológica em Reabilitação, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brasil, 2 Faculdade de Ciências da Saúde do Trairi, Universidade Federal do Rio Grande do Norte, Santa Cruz, Rio Grande do Norte, Brasil, 3 Dipartimento di Elettronica, Informazione e Bioingegneria, Politecnico di Milano, Milan, Italy

☯ These authors contributed equally to this work.

* vanessa.resqueti@ufrn.br

Abstract

Introduction

In subjects with obstructive respiratory diseases the increased work of breathing during exercise can trigger greater recruitment and fatigue of respiratory muscles. Associated with these changes, lower limb muscle dysfunctions, further contribute to exercise limitations. We aimed to assess electrical activity and fatigue of two respiratory and one locomotor muscle during Incremental Shuttle Walking Test (ISWT) in individuals with obstructive respiratory diseases and compare with healthy.

Methods

This is a case-control study. Seventeen individuals with asthma (asthma group) and fifteen with chronic obstructive pulmonary disease (COPD group) were matched with healthy individuals (asthma and COPD control groups). Surface electromyographic (sEMG) activity of sternocleidomastoid (SCM), scalene (ESC), and rectus femoris (RF) were recorded during ISWT. sEMG activity was analyzed in time and frequency domains at baseline and during the test (33%, 66%, and 100% of ISWT total time) to obtain, respectively, signal amplitude (EMG median frequency [MF], high- and low-frequency bands, and high/low [H/L] ratio).

Results

Asthma group walked a shorter distance than controls (p = 0.0007). sEMG amplitudes of SCM, ESC, and RF of asthma and COPD groups were higher at 33% and 66% of ISWT compared with controls groups (all p<0.05). SCM and ESC of COPD group remained higher until 100% of the test. MF of ESC and RF decreased in asthma group (p = 0.016 and p < 0.0001, respectively) versus controls, whereas MF of SCM (p < 0.0001) decreased in...
COPD group compared with controls. H/L ratio of RF decreased (p = 0.002) in COPD group versus controls.

**Conclusion**

Reduced performance is accompanied by increased electromyographic activity of SCM and ESC and activation of RF in individuals with obstructive respiratory diseases during ISWT. These are susceptible to be more pronounced respiratory and peripheral muscle fatigue than healthy subjects during exercise.

**Introduction**

Obstructive respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are characterized by persistent respiratory symptoms, including dyspnea, wheeze, coughing, and increased sputum production associated with limited expiratory airflow [1, 2]. During exercise, ventilatory demand increases and overloads inspiratory muscles [3, 4], with disproportionate increase in neural respiratory drive directed towards the respiratory muscles [5, 6]. Increased work of breathing during exercise may lead to respiratory muscle fatigue and worsen the sensation of dyspnea. Individuals with asthma and COPD can present dysfunction of locomotor muscles [7–11] due to changes in peripheral structures and energy metabolism [7, 12], increasing the risk of peripheral fatigue during exercise.

Muscle fatigue is defined as a reduction in maximum capacity to generate force or power output [13] resulted from insufficient oxygen, supply of nutritive substances, and decreased removal of local by-products [14]. In this context, the lower blood flow disponibility may increase susceptibility to early peripheral fatigue since the increased work of breathing on exercise, deviating blood flow from locomotor to respiratory muscles [15, 16]. Therefore, events associated with intrinsic changes in locomotor muscles may impact exercise tolerance in individuals with obstructive respiratory diseases [17].

Surface electromyography (sEMG) is a valuable technique to assess muscle function [18] and provide real-time information about muscle activation and fatigue development [19]. sEMG signal amplitude is sensitive to motor unit recruitment and represents the magnitude of muscle activation [20], whereas changes in power spectrum density are attributed to muscle fiber conduction velocity [21] and activity of remaining slow motor units [14]. Changes in power spectrum can also indicate fatigue development through methods, such as median frequency (MF), high- and low-frequency bands, and high/low (H/L) ratio [22, 23].

Mechanical abnormalities in individuals with obstructive respiratory diseases alter the load-capacity balance of the respiratory system, contributing to greater neural respiratory drive and inspiratory muscle recruitment during exercise. Also, locomotor muscles dysfunction associated with blood flow competition between respiratory and locomotor muscles may further compromise symptoms, leading to early exercise interruption. Cardiopulmonary exercise test is commonly used to identify exercise limitation due to respiratory and locomotor muscle commitments [24]; however, activation of these muscles during field walking tests that reproduce daily activities (e.g., incremental shuttle walking test [ISWT]) has been under-investigated. We hypothesize that individuals with chronic respiratory diseases have greater activations and develop respiratory and locomotor muscles fatigue during daily activities, compared to healthy individuals. Therefore, this study aimed to assess respiratory and
locomotor muscles activation and fatigue development during ISWT in individuals with obstructive respiratory diseases.

**Methods**

This case-control study followed the Declaration of Helsinki and was approved by the research ethics committee of the Hospital Universitário Onofre Lopes (HUOL)/Empresa Brasileira de Serviços Hospitalares (EBSERH) (number 1.344.501). All participants signed the informed consent form.

**Subjects**

Were included 17 individuals with clinical diagnosis of asthma (asthma group) (aged between 25–60 years) and 15 COPD subjects (COPD group) (aged between 50–80 years), from both genders, under medical supervision, without disease exacerbation in the last four weeks, body mass index less than 30 kg/m², and non-smokers. The difference in age range between groups was due to clinical phenotype of late-onset asthma that starts in adulthood [1]. For COPD subjects, age was chosen due to highest prevalence among those aged >60 years in Brazil [2]. All individuals were matched for age, sex, and BMI with self-reported healthy individuals, non-smokers, and without impaired lung function (17 matched with asthmatics [asthma control group] and 15 matched with COPD subjects [COPD control group]) (Fig 1). Individuals with asthma-COPD overlap syndrome, cognitive or osteoarticular deficits compromising data collection, and those who exacerbated during the study period were excluded.

**Study design**

The study protocol was conducted in two moments: 1) anthropometric data (shown in Table 1), pulmonary function and respiratory muscle strength assessment and 2) ISWT. Assessments were performed in two non-consecutive days with maximum interval of seven days in between.

![Flowchart selection of participants.](https://doi.org/10.1371/journal.pone.0266365.g001)
Pulmonary function and respiratory muscle strength

Pulmonary function was assessed by spirometry test using the Koko® spirometer (model 313106, Longmont, USA), following reproducibility and acceptability criteria of the American Thoracic Society/European Respiratory Society [25]. Post-bronchodilator spirometry was performed in individuals with asthma and COPD using 400 mcg of salbutamol sulfate. Reversibility criteria followed GINA [1] recommendations for individuals with asthma and GOLD [2] recommendations for individuals with COPD. Absolute values and percentage of predicted forced vital capacity (FVC), forced expiratory volume in the first second (FEV₁) and FEV₁/FVC ratio values were considered and compared with predicted for the Brazilian population [26].

Respiratory muscle strength was assessed by volitional measurement of maximal respiratory pressure at the mouth (Maximal Inspiratory Pressure—MIP and Maximal Expiratory Pressure–MEP) and at nostril (Sniff Nasal Inspiratory Pressure–SNIP). We used a digital manovacuometer (NEPEB—LabCare/ UFMG, Belo Horizonte—MG, Brazil) to measure MIP, MEP, and SNIP tests following the American Thoracic Society/European Respiratory Society Statement [18]. Predicted values for MIP and MEP followed Neder et al. [27], while Araújo et al. [28] were used for SNIP.

Incremental shuttle walking test

The ISWT was used to assess the exercise capacity, according to Singh et al. [29]. The primary result is the distance walked in meters. Subjects walked in a flat corridor at a 10 meters distance around two cones placed 9 meters apart. The two cones were inset 0.5 m from either end to avoid the need for abrupt changes in direction. The walking speed was determined by an audio signal, in which the test level changed every minute, stimulating the participant to increase their walking speed. Predicted walking distances were calculated according to Jürgensen et al. [30]. Respiratory rate (RR), dyspnea, and lower limb fatigue (modified Borg scale 0–10) were evaluated before and after ISWT. The RR was evaluated by counting respiratory incursions in one minute. Heart rate and peripheral oxygen saturation (SpO₂) were monitored before, during, and after the test using a pulse oximeter (MODEL 2500®, Plymouth, Minnesota —USA).

Table 1. Anthropometric characteristics of the sample.

|                                | Asthma group (n = 17) | Control group (n = 17) | 95%CI | COPD group (n = 15) | 95%CI | Difference (95%CI) | p    | Control group (n = 15) | 95%CI | COPD group (n = 15) | 95%CI | Difference (95%CI) | p    |
|--------------------------------|-----------------------|------------------------|-------|---------------------|-------|--------------------|------|------------------------|-------|---------------------|-------|--------------------|------|
| Age (years)                    | 34.76 ± 11.18         | 29.01–40.51            | 33.88 ± 12.66  | 27.37–40.39        | -0.88 (9.22–7.46) | 0.83          | 65.6 ± 7.84         | 61.26–69.94        | 65.13 ± 7.79        | 60.82–69.45        | -0.46 (6.31–5.38) | 0.87 |
| Sex                            | F: 15                 | M: 2                   | F: 15          | M: 2                | F: 10  | M: 5               |      | F: 10                 | M: 5              | -                  | -     | 65.6 ± 7.84         | 61.26–69.94        | 65.13 ± 7.79        | 60.82–69.45        | -0.46 (6.31–5.38) | 0.87 |
| Body weight (kg)               | 62.84 ± 9.19          | 58.11–67.57            | 61 ± 5.11      | 58.37–63.63        | -1.84 (7.03–3.33) | 0.47          | 71.93 ± 12.23       | 65.16–78.70        | 64.53 ± 13.79       | 56.89–72.17        | -7.4 (17.15–2.34) | 0.13 |
| Height (m)                    | 1.60 ± 0.10           | 1.54–1.65              | 1.64 ± 0.07    | 1.60–1.68          | 0.03 (0.02–0.10) | 0.22          | 1.57 ± 0.06         | 1.53–1.60          | 1.54 ± 0.11         | 1.48–1.61          | -0.02 (0.09–0.04) | 0.44 |
| BMI (Kg/m²)                   | 24.66 ± 4.08          | 22.56–26.76            | 22.65 ± 2.02   | 21.6–23.69         | -2.01 (4.26–0.24) | 0.07          | 28.97 ± 3.91        | 26.80–31.14        | 26.84 ± 3.29        | 25.01–28.66        | -2.13 (4.84–0.57) | 0.11 |

Data reported as mean ± standard deviation. F: female. M: male. Kg: kilograms. m: meters. BMI: body mass index. Kg/m²: kilogram per square meter.

https://doi.org/10.1371/journal.pone.0266365.t001
sEMG activity
sEMG activity of sternocleidomastoid (SCM), scalene (ESC), and rectus femoris (RF) muscles were recorded during ISWT. A TeleMyo DTS Desk Receiver electromyograph (Noraxon®, Scottsdale—USA) with four wireless sensors (Noraxon®, Scottsdale—USA), 16-bit resolution, and common-mode rejection ratio of >100 dB was used. sEMG data were captured at a sampling frequency of 1500 Hz, with low-pass filter of 500 Hz, amplified 1000 times, and stored in the MR 3.12 software (Noraxon®, Scottsdale—USA). Bipolar electrodes with 20 mm inter-electrode distance and contact surface in gel and silver/silver chloride were used. Skin preparation followed SENIAM guidelines (Surface EMG for Non-Invasive Assessment of Muscles) [31]. Electrode positioning followed anatomical references and muscle fiber orientation of SCM (lower third of the distance between sternoclavicular joint and mastoid process) [32], ESC (five centimeters from sternoclavicular joint and two centimeters above this point) [33], and RF (half distance between upper anterior iliac spine and superior portion of the patella) [34]. All electrodes were positioned on the right side of the body to avoid noise and interference from cardiac electrical activity.

sEMG signal processing
Time-domain analysis was performed to obtain signal amplitudes (i.e., root mean square [RMS]) at baseline, 33%, 66%, and 100% of ISWT total time using MR 3.12 software (Noraxon, Scottsdale-USA). Raw sEMG data were filtered with a high-pass filter, cut-off frequency at 20 Hz, rectified with full-wave rectifier, and smoothened with RMS algorithm in a time window of 50 ms. Electrocardiogram filter was applied to reduce noise caused by cardiac activity. RMS data were normalized by peak value achieved during ISWT [35].

Frequency domain analysis was performed to identify fatigue development as a shift of the sEMG power spectrum toward lower frequencies [36]. sEMG signals were processed offline using MATLAB R2018a (Mathworks, Natick, MA). Power spectral density was calculated applying the continuous Wavelet transform technique using Daubechies 4 mother wavelet. For each power spectrum, the median frequency was calculated. Analysis was performed in 5-s time windows, and sEMG signals were digitized with a band-pass filter (fourth-order Butterworth filter, 20–500 Hz).

For a complete analysis of changes in power spectrum density, relative contributions of high- and low-frequency bands and H/L frequency ratio were computed by filtering the signal with different bandpass filters and integrating each filtered output to obtain high- and low-frequency powers. Shifts in spectral properties of frequency bands (e.g., lower overall power spectrum) are linked to changes in motor unit recruitment priority (e.g., higher contribution of low-frequency motor units) [37]. For respiratory muscles, high-frequency band was defined at 130–250 Hz and low frequency at 30–50 Hz [18]. For peripheral muscles, high and low-frequency bands were defined as 194–250 Hz and 27–48 Hz, respectively [37]. Frequency bands and H/L ratio were normalized for each participant and expressed as percentage of values obtained in the initial 10 s of the test. This normalization allowed comparison between participants since fatigue was not present at the beginning of the test.

Since MF and H/L ratio may show different decay patterns during the task, one of the following criteria should be met to confirm fatigue development: 1) negative slopes for linear regressions, representing displacement of frequency to lower values [38] or 2) decrease below 60% of values recorded at the beginning of the test for exponential regressions, as observed in human diaphragm and skeletal muscles [39].
Sample size calculation and statistical analysis

Sample size was calculated in a pilot study with asthma and healthy subjects (GPower 3.1 software) using RMS of SCM at 100% total ISWT time. With an effect size of 0.8, 80% statistical power, and significance level of 0.5, a sample size of 21 participants was estimated. GraphPad Prism 6.0 software was used to perform statistical analyses, assuming a significance level of \( p < 0.05 \). Shapiro-Wilk test verified data normality. Unpaired t-tests were performed to analyze anthropometric data, lung function, and ISWT performance. Mann-Whitney test was performed for cardiorespiratory variables, dyspnea, lower limb fatigue, and sEMG activity. Friedman with Dunn’s post-hoc was performed for intragroup analyzes regarding ISWT moments and baseline. Regression analysis was also performed to determine \( r^2 \) and extract slopes for MF, high- and low-frequency bands, and H/L ratio during ISWT. Slopes of regression were also calculated between groups by the F-test. For Mann-Whitney test, Cohen’s d was calculated to estimate effect sizes, and values interpreted as large (0.5), medium (0.3), and small (0.1) [40]. For Friedman test, effect sizes were estimated using Kendall’s W coefficient, ranging from 0 (no relationship) to 1 (perfect relationship) [41].

Results

The final sample of individuals with obstructive respiratory diseases was classified as six individuals from the asthma group with mild (35%) and 11 (64%) with moderate asthma disease [1]. Eight individuals from the COPD group had GOLD 2 (53%) and seven (46%) as GOLD 3 [2]. Pulmonary function and respiratory muscle strength data of the sample studied are shown in Table 2.

ISWT performance

Walking distance was 26% shorter for asthma group than asthma control group in both absolute (\( p = 0.007; \) Cohen’s d = 0.45) and predicted values (\( p = 0.0001, \) Cohen’s d = 0.45). No difference (\( p > 0.05 \)) was found between COPD group and COPD control group. However, at the end of ISWT, COPD group showed lower \( \text{SpO}_2 \) and greater RR, dyspnea, and lower limb fatigue than COPD control group (Table 3).

Amplitude of EMG signals during ISWT

**Sternocleidomastoid muscle (SCM).** %RMS of SCM was greater in asthma group than asthma control group at baseline (\( p = 0.003 \)), 33% (\( p = 0.0005 \)), and 66% (\( p = 0.004 \)) of total ISWT time. %RMS of SCM in asthma group increased immediately after initiating the test (33% ISWT moment) and continued rising until the end of the test (\( p < 0.0001, \) Kendall’s W = 0.83). In contrast, sEMG activity of SCM increased in asthma control group only between 66% and 100% of total ISWT time (\( p < 0.0001, \) Kendall’s W = 0.88) (Fig 2A). %RMS of SCM was also greater in COPD group than COPD control group at 33% (\( p = 0.009 \)), 66% (\( p = 0.023 \)), and 100% (\( p = 0.023 \)) of total ISWT time. %RMS of SCM increased between 66% and 100% of total ISWT time in both COPD (\( p < 0.0001, \) Kendall’s W = 0.70) and COPD control groups (\( p < 0.0001, \) Kendall’s W = 0.81) (Fig 2D).

**Scalene muscle (ESC).** %RMS of ESC was greater in asthma group than asthma control group at baseline (\( p = 0.017 \)), 33% (\( p = 0.001 \)), and 66% (\( p = 0.033 \)) of total ISWT time. In asthma group, %RMS of ESC increased almost immediately after initiating the test (\( p < 0.0001, \) Kendall’s W = 0.81), while in asthma control group the activity increased between 66% and 100% of total ISWT time (\( p < 0.0001, \) Kendall’s W = 0.86) (Fig 2B). %RMS of ESC was higher in COPD group than COPD control group at 33% (\( p = 0.006 \)), 66% (\( p = 0.008 \)),...
Table 2. Pulmonary function data of the sample.

|                     | Asthma group  | 95%CI | Control group | 95%CI | Difference (95%CI) | p   | COPD group  | 95%CI | Difference (95%CI) | p   | Control group | 95%CI | Difference (95%CI) | p   |
|---------------------|---------------|-------|---------------|-------|--------------------|-----|-------------|-------|--------------------|-----|---------------|-------|--------------------|-----|
| FVC (L)             | 3.37 ± 0.72   | 3–3.75 | 3.51 ± 0.57   | 3.21–3.89 | 0.13 (–0.32–0.59) | 0.55 | 1.88 ± 0.44 | 1.64–2.13 | 2.82 ± 0.47 | 2.56–3.09 | 0.93 (0.59–1.28) | <0.0001* |
| FVC (% pred)        | 91.41 ± 13.60 | 84.42–98.40 | 92.03 ± 8.6  | 87.57–96.50 | 0.62 (–7.35–8.59) | 0.87 | 63.46 ± 13.73 | 55.85–71.06 | 98.12 ± 19.40 | 87.38–108.9 | 34.66 (22.09–47.23) | <0.0001* |
| FEV1 (L)            | 2.36 ± 0.57   | 2.07–2.66 | 2.87 ± 0.54   | 2.59–3.15  | 0.50 (0.11–0.90)  | 0.01 | 1.17 ± 0.3  | 1–1.34 | 2.18 ± 0.36 | 1.98–2.39 | 1.01 (0.76–1.26) | <0.0001* |
| FEV1 (% pred)       | 77.20 ± 17.23 | 68.34–86.06 | 91.16 ± 6.25  | 87.95–94.38 | 13.96 (4.90–23.02) | 0.003 | 48.72 ± 15.81 | 39.96–57.48 | 95.24 ± 19.74 | 84.31–106.2 | 46.52 (33.14–59.89) | <0.0001* |
| FEV1/FVC            | 0.70 ± 0.10   | 0.64–0.75 | 0.82 ± 0.05   | 0.80–0.85  | 0.12 (0.06–0.18)  | 0.0001 | 0.62 ± 0.07 | 0.58–0.67 | 0.77 ± 0.07 | 0.73–0.82 | 0.15 (0.09–0.21) | <0.0001* |
| MIP50 pred          | 91.86 ± 23.34 | 79.86–103.9 | 113.9 ± 27.07 | 100–127 | 22.08 (4.42–39.74) | 0.015 | 89.21 ± 23.65 | 76.11–102.3 | 90.05 ± 19.79 | 79.10–101 | 0.84 (-15.46–17.16) | 0.91 |
| MEP50 pred          | 86.22 ± 19.93 | 75.97–96.46 | 116.8 ± 26.98 | 102.9–130.7 | 30.58 (14.01–47.15) | 0.0007 | 92.85 ± 13.55 | 85.35–100.4 | 95.89 ± 16.98 | 86.49–105.3 | 3.04 (-8.45–14.53) | 0.59 |
| SNP50 pred          | 79.84 ± 23.37 | 67.83–91.85 | 98 ± 22       | 86.69–109.3 | 18.16 (2.30–34.02) | 0.026 | 70.94 ± 20.28 | 59.71–82.17 | 81.05 ± 10.96 | 74.98–87.12 | 10.11 (-2.07–22.30) | 0.10 |

Data reported as mean ± standard deviation. FVC: forced vital capacity. FEV1: forced expiratory volume in the first second. FEV1/FVC: FEV1/FVC ratio. MIP: maximal inspiratory pressure. MEP: maximal expiratory pressure. SNP: sniff nasal inspiratory pressure. L: liters %pred; % predicted.

* Unpaired t-test.

https://doi.org/10.1371/journal.pone.0266365.t002

and 100% (p = 0.016) of total ISWT time. Similar to SCM, both groups demonstrated increased %RMS of ESC between 66% and 100% of total ISWT time (p < 0.0001, Kendall’s W = 0.69 for COPD group and p < 0.0001, Kendall’s W = 0.61, for COPD control group) (Fig 2E).

Table 3. Results of ISWT.

| ISWT                | Asthma group  | 95%CI | Control group | 95%CI | Difference (95%CI) | p   | COPD group  | 95%CI | Difference (95%CI) | p   | Control group | 95%CI | Difference (95%CI) | p   |
|---------------------|---------------|-------|---------------|-------|--------------------|-----|-------------|-------|--------------------|-----|---------------|-------|--------------------|-----|
| ISWT (m)            | 445.15 ± 126  | 380.3–599.8 | 607.8 ± 1277 | 542.5–673.1 | 162.8 (74.39–251.3) | 0.0007 | 275.3 ± 87.47 | 226.7–323.9 | 302.7 ± 91.53 | 252–353.4 | 27.33 (–39.73–94.39) | 0.41 |
| ISWT (%pred)        | 71.78 ± 18.01 | 62.52–81.04 | 93.40 ± 94.43 | 88.55–98.25 | 21.62 (11.57–31.66) | 0.0001 | 67.84 ± 19.35 | 57.12–78.55 | 73.63 ± 22.25 | 61.31–85.95 | 5.79 (–9.80–21.39) | 0.45 |
| Borg D (0–10)       | 3 [0.5–3]     | 1.14–3.26 | 3 [2–4]       | 1.86–3.31  | 0 (–1–2) | 0.35 | 2 [1–3] | 1.58–2.41 | 1 [0–1] | 0.54–1.3 | -1 (–2–1) | 0.001† |
| Borg F (0–10)       | 1 [0.5–4]     | 1.18–3.40 | 2 [1–4]       | 1.37–3.21  | 1 (1–1.5) | 0.80 | 4 [2–5] | 2.88–4.58 | 3 [2–3] | 2.25–2.95 | -1 (–2–0) | 0.025† |
| HR (bpm)            | 78 [73.5–92]  | 87.46–113.1 | 124 [101–143] | 106.5–133.4 | 24 (2–42) | 0.03† | 93 [87–100] | 87.5–97.44 | 89 [81–101] | 83.61–97.19 | -4 (–12–6) | 0.45 |
| SpO2 (%)            | 98 [97.9–98.5] | 96.72–98.57 | 98 [98–99] | 97.65–98.70 | 0 (–1–1) | 0.66 | 92 [90–94] | 90.25–93.49 | 96 [96–97] | 95.5–96.9 | 4 (3–6) | <0.0001† |
| RR (bpm)            | 20 [18–22]    | 20.6–25.53 | 24 [20–29.5] | 21.13–26.99 | 0 (–3–5) | 0.67 | 21 [18–22] | 19.3–21.9 | 18 [16–20] | 17.26–19.14 | -3 (–4–1) | 0.004† |

Data presented as mean ± standard deviation for ISWT distance and ISWT%pred. Data presented as medians [interquartile range] for D (dyspnea), F (fatigue), HR (heart rate), SpO2 (oxygen saturation) and RR(respiratory rate). bpm: beats per minute. Bpm: breath per minute %pred; % predicted. m: meters.

* Unpaired t-test.
† Mann-Whitney Test: p < 0.05 between groups.

https://doi.org/10.1371/journal.pone.0266365.t003
Rectus femoris (RF). %RMS of RF was greater in asthma group at 33% (p = 0.02) and 66% (p = 0.004) of total ISWT time. In asthma group, %RMS of RF increased immediately after initiating ISWT (33% ISWT moment) (p < 0.0001, Kendall’s W = 0.82). In asthma control group, %RMS of RF increased from 66% of total ISWT time (p < 0.0001, Kendall’s W = 0.87) (Fig 2C). COPD group was significantly different from COPD control group at 33% (p = 0.032) and 66% (p = 0.039) of total ISWT time. In both groups, %RMS of RF also increased at 33% of ISWT (p < 0.0001, Kendall’s W = 0.86 for the COPD group and p < 0.0001, Kendall’s W = 0.82 for the COPD control group) (Fig 2F). Effect sizes and differences [95%CI] between groups for all muscles evaluated are shown in Table 4.

Power spectrum density of sEMG signal during ISWT. MF slopes decreased linearly in all muscles during ISWT. Moreover, intergroup differences were observed for ESC (p = 0.016) and RF (p < 0.0001) muscles with higher slopes in asthma group (Fig 3). MF decreased linearly in SCM and RF of COPD group. Slopes were different for SCM (p < 0.0001) in intergroup

Table 4. Effect size and difference (95% CI) values of EMGs amplitude between groups.

|                     | **Asthma group (n = 17) vs. Control group (n = 17)** | **COPD group (n = 15) vs. Control group (n = 15)** |
|---------------------|------------------------------------------------------|-----------------------------------------------------|
|                     | **Cohen’s d** | **Difference (95%CI)** | **Cohen’s d** | **Difference (95%CI)** |
| SCM                 |             |                         |             |                         |
| Baseline            | 0.56        | -3.83 (-5.29 to -1.49) | -            | -                      |
| 33%                 | 0.49        | -6.58 (-7.78 to -5.16) | 0.47        | -5.28 (-8.48 to -1.57) |
| 66%                 | 0.35        | -4.06 (-5.85 to -0.06) | 0.41        | -4.41 (-7.86 to -0.37) |
| 100%                | -           | -                       | 0.41        | -5.14 (-8.78 to -0.60) |
| ESC                 |             |                         |             |                         |
| Baseline            | 0.33        | 2.45 (-3.61 to -0.58)  | -           | -                      |
| 33%                 | 0.43        | -3.70 (-5.73 to -1.47) | 0.49        | -4.41 (-6.62 to -1.22) |
| 66%                 | 0.30        | -3.30 (-5.57 to -0.19) | 0.47        | 2.19 (-8.62 to 0.87)   |
| 100%                | -           | -                       | 0.43        | -2.14 (-10.13 to -0.46) |
| RF                  |             |                         |             |                         |
| Baseline            | -           | -                       | -           | -                      |
| 33%                 | 0.32        | -2.95 (-4.30 to -1.05)  | 0.39        | -1.45 (-3.31 to 0.09)  |
| 66%                 | 0.40        | -2.31 (-4.18 to -0.47)  | 0.37        | -1.24 (-4.5 to 0.12)   |
| 100%                | -           | -                       | -           | -                      |

https://doi.org/10.1371/journal.pone.0266365.t004
analysis with higher slopes in COPD group (Fig 4). Slopes of MF for RF between COPD subjects and controls were not calculated due to different decay patterns.

High-frequency band of ESC and RF decreased linearly in asthma group, whereas low-frequency band increased linearly in all muscles of both groups. H/L ratio decreased linearly in all assessed muscles of both groups. Slopes of power spectrum of assessed muscles were not different between groups (Fig 5).

High-frequency band decreased linearly in SCM and RF muscles of COPD group. Inter-group differences were observed in slopes of high-frequency bands of ESC (p < 0.0001) and RF (p = 0.014). Low-frequency band of RF increased linearly in COPD group, and slopes were significantly greater in COPD group (p < 0.0001). H/L ratio of SCM and RF muscles decreased linearly in COPD group. COPD group exhibited greater slope values of H/L ratio in ESC (p < 0.0001) and RF (p = 0.002) compared with controls (Fig 6).

Fig 3. sEMG frequency median of SCM (A and D), ESC (B and E), and RF (C and F) muscles on ISWT, in Asthma-group (close circles) on upper panel and control group (open square) on the lower panel.

https://doi.org/10.1371/journal.pone.0266365.g003

Fig 4. sEMG frequency median of SCM (A and D), ESC (B and E), and RF (C and F) muscles on ISWT, in COPD-group (close triangles) on upper panel and control group (open square) on the lower panel.

https://doi.org/10.1371/journal.pone.0266365.g004
Discussion

The present study aimed to assess surface electrical activity and fatigue development of respiratory (sternocleidomastoid and scalene) and locomotor (rectus femoris) muscles using sEMG during ISWT in individuals with obstructive respiratory diseases versus healthy individuals. Main findings of the present study were that 1) individuals with COPD and asthma presented greater sEMG amplitude of respiratory peripheral muscles during ISWT than healthy individuals; 2) individuals with asthma presented onset of fatigue development according to decreased MF of ESC and RF muscles; 3) fatigue development of SCM and RF in individuals with COPD were reflected by MF decrease and power spectrum distribution, respectively, compared with healthy individuals.
sEMG amplitude of respiratory muscles increased throughout ISWT and was higher in individuals with obstructive respiratory disease than healthy controls. Individuals with asthma have persistent inspiratory muscle activity [42]. In individuals with COPD, greater activation of ESC and intercostal muscles during maximum incremental exercise were associated with increased dyspnea [5]. Such findings corroborate those found in our study. Work of breathing increases during exercise due to functional respiratory muscle weakness (i.e., result of muscle shortening and abnormal geometry) in subjects with asthma and COPD [4, 43]; thus, increasing neural respiratory drive to diaphragm and pulmonary rib cage muscles (i.e., parasternal, intercostal, SCM, and ESC) [3, 44]. sEMG can accurately reflect neural respiratory drive to

Fig 6. The high and low frequency bands, and high/low ratio of SCM (A, D, G, J, M and P), ESC (B, E, H, K, N and Q), and RF (C, F, I, O and R) muscles on ISWT moments, in COPD group (close triangles) and control group (open square).

https://doi.org/10.1371/journal.pone.0266365.g006
inspiratory muscles during exercise [5]. We believe that increased sEMG amplitude of respiratory muscles in individuals with obstructive respiratory disease reflects loads imposed on respiratory muscles triggered by mechanical abnormalities (dynamic hyperinflation, increased minute ventilation and respiratory rate, and intrinsic positive end-expiratory pressure) [6].

Activation of respiratory muscles was coordinated with RF in all individuals. Respiratory diseases impose a risk for locomotor muscle dysfunction [7, 12] due to physical inactivity, disuse, and chronic exposure to systemic corticosteroids. In the present study, individuals with chronic respiratory diseases were using medication to control the disease. Dysfunction of locomotor muscles includes changes in fiber distribution (from type I to type II), muscle atrophy and mitochondrial dysfunction, and reduced muscle capillarity and oxidative capacity [6, 7, 9]. Increased electrical activation corroborates the notion that atrophic muscles require increased activation for achieving a given strength or task than trained muscles [45]. Thus, we believe that greater activation of RF in this population is attributed to locomotor muscle deconditioning since these individuals are exposed to structural, metabolic, and energetic changes, mainly in the quadriceps femoris muscle.

MF of ESC and SCM reduced linearly during ISWT in asthma group and COPD groups, respectively, indicating fatigue development [36]. Despite the obstructive pattern, both diseases exhibited particularities that could explain these findings. Individuals with asthma were younger, presented lower obstruction levels (FEV₁ = 77.20%) than those with COPD, and activated ESC during exercise. Although greater activation of SCM was also observed in individuals with asthma, this muscle may have not developed fatigue during ISWT. On the other hand, higher obstruction levels in COPD may have altered diaphragm geometry and reduced capacity of inspiratory muscles to generate negative intrathoracic pressure [46]. Consequently, greater rib cage muscle recruitment (including SCM) is needed to increase ventilation during exercise.

Moreover, SCM is composed of a larger proportion of type II fibers (65%) [47] than ESC (39%) [48]. Therefore, higher concentrations of metabolites (i.e., H+ ions and lactic acid) are produced, reducing intramuscular pH and muscle fiber conduction velocity, and shifting power spectrum to lower frequencies [21]. In this context, we suggest that fatigue development of SCM was higher in individuals with COPD, whereas fatigue development of ESC was more pronounced in asthmatic individuals.

The MF of RF of individuals with asthma and COPD also declined during the test. Although power spectrum and H/L ratio were similar between asthma and control groups, the decline in slope of MF was significantly higher in the former, which presented worse ISWT performance. H/L ratio and high- and low-frequency bands were different between COPD and control groups. Based on previous studies that observed a decline in MF of RF during dynamic contractions associated with power spectrum changes [49], we believe that declined MF found in our study was related to enhanced recruitment of slow-firing, fatigue-resistant motor units and/or reduced recruitment of rapid-firing, fatigable motor units. Therefore, RF developed fatigue during ISWT in both groups, but mainly in the COPD group, which experienced fatigue at the end of the test.

Susceptibility to lower limb muscle fatigue may be also related to blood flow distribution to respiratory muscles during exercise. Because of muscle metaboreflex activation, respiratory muscles initiate a blood flow "stealing effect" that compromises oxygen support and removal of metabolic by-products to activated locomotor muscles [16, 43, 50]. Based on recent evidence, the changes in power spectrum density of RF in individuals with obstructive respiratory disease may have been indirectly influenced by such events.

Our findings suggest that decreased MF and changes in power spectrum density of respiratory and locomotor muscles may be attributed to fatigue development during ISWT, especially
in COPD individuals. In asthmatics, isolated analysis of MF decay in RF muscle provides incomplete information about changes in power spectrum density during fatigue development. Changes in frequency bands are attributed to underlying physiological mechanisms, but this information cannot be revealed if only MF is considered. To our knowledge, literature lacks simultaneous sEMG evaluation of respiratory and locomotor muscles during field walking tests in individuals with obstructive respiratory diseases. Our study helps to fill this gap in the literature since sEMG provides a non-invasive alternative for assessing the behavior of respiratory and locomotor muscles during dynamic exercise. Furthermore, sEMG data can assist in interpreting changes in activation and fatigue development of respiratory and locomotor muscles during rehabilitation.

This study has limitations that should be considered. We are aware that SCM and ESC might also have been activated during neck rotation when changing directions in the ISWT. Future research must include diaphragm, rib cage, and abdominal muscles [43] to enhance comprehension of respiratory muscle action during field walking tests. Besides, sEMG alone is insufficient to confirm muscle metaboreflex. Therefore, future researchers using sEMG combined with advanced resources to assess blood flow and respiratory and locomotor oxygenation (e.g., near-infrared spectroscopy—NIRS) are needed.

**Conclusion**

Individuals with obstructive respiratory disease exhibit increased electrical activity of respiratory and locomotor muscles during ISWT compared with healthy individuals. Fatigue development in these muscles is also related to low performance in the ISWT.

**Supporting information**

**S1 File.**

(RAR)

**Author Contributions**

**Conceptualization:** Guilherme Augusto F. Fregonezi, Vanessa R. Resqueti.

**Data curation:** Jéssica D. Cavalcanti.

**Formal analysis:** Antonio J. Sarmento, Thiago Bezerra, Lucien P. Gualdi, Vanessa R. Resqueti.

**Methodology:** Jéssica D. Cavalcanti, Thiago Bezerra, Lucien P. Gualdi, Francesca Pennati, Andrea Aliverti, Vanessa R. Resqueti.

**Project administration:** Jéssica D. Cavalcanti, Guilherme Augusto F. Fregonezi, Vanessa R. Resqueti.

**Software:** Francesca Pennati, Andrea Aliverti.

**Supervision:** Guilherme Augusto F. Fregonezi, Vanessa R. Resqueti.

**Validation:** Guilherme Augusto F. Fregonezi, Vanessa R. Resqueti.

**Visualization:** Guilherme Augusto F. Fregonezi.

**Writing – original draft:** Jéssica D. Cavalcanti.

**Writing – review & editing:** Jéssica D. Cavalcanti, Guilherme Augusto F. Fregonezi, Antonio J. Sarmento, Thiago Bezerra, Lucien P. Gualdi, Francesca Pennati, Andrea Aliverti, Vanessa R. Resqueti.
References

1. GINA—Global Initiative for Asthma [homepage on the Internet]. Global Strategy for Asthma Management and Prevention, 2020. [Adobe Acrobat document, 209p.] Available in: www.ginasthma.org.

2. GOLD–Global Initiative for Chronic Obstructive Lung Disease [homepage on the Internet]. Global Strategy for the diagnosis, management, and prevention of Chronic Obstructive Pulmonary Disease, 2021. [Adobe Acrobat document, 152p.] Available in: www.goldcopd.org.

3. Jolley C.J., Luo Y.M., Steier J., Reilly C., Seymour J., Lunt A., et al. Neural respiratory drive in healthy subjects and in COPD. Eur Respir J 2009; 33: 289–297. https://doi.org/10.1183/09031936.0009408 PMID: 18829678

4. Weatherald J., Lougheed M. D., Taille à and C., Garcia G. Mechanisms, measurement and management of exertional dyspnoea in asthma. Eur Respir Rev 2017; 26: 170015. https://doi.org/10.1183/16000617.0015-2017 PMID: 28615308

5. Dulverman M.L., De Boer E.W.J., Van Eykernc L.A., De Greef M.H.G., Jansen D.F., Wempe J.B., et al. Respiratory muscle activity and dyspnea during exercise in chronic obstructive pulmonary disease. Respir Physiol & Neurobiol 2009; 167: 195–200. https://doi.org/10.1016/j.resp.2009.04.018 PMID: 19406254

6. Jolley C.J., Moxham J. A physiological model of patient-reported breathlessness during daily activities in COPD Eur Respir Rev 2009; 18: 112, 66–79. https://doi.org/10.1183/09059180.00000809 PMID: 20956127

7. Maltais F., Decramer M., Casaburi R., Barreiro E., Burelle Y., et al. An Official American Thoracic Society/European Respiratory Society Statement: Update on Limb Muscle Dysfunction in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2014; 189 (9): 1121–1137. https://doi.org/10.1164/rccm.201402-0373ST PMID: 24787074

8. Decramer M., Lacquet L. M., Fagard R., Rogiers P. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150: 11–16. https://doi.org/10.1164/ajrccm.150.1.8665061 PMID: 8665061

9. Ramos E., Oliveira L.V.F., Silva A.B., Costa I.P., Corrêa J.C.F., et al. Peripheral muscle strength and functional capacity in patients with moderate to severe asthma. Multidiscip Resp Med 2015; 10(3): 1–7. https://doi.org/10.1186/s40266-015-0084-4 PMID: 25973197

10. Canuto F.F., Silva S.M., Sampaio L.M.M., Stirbulov R., Corrêa J.C.F. Neurophysiological and functional assessment of patients with difficult-to-control asthma. Rev. Port. Pneumol 2012; 18 (4): 160–165. https://doi.org/10.1016/j.rppneu.2012.02.008 PMID: 22541671

11. Vermeulen F. Garcia G., Ninane V., Laveneziana P. Activity limitation and exertional dyspnea in adult asthmatic patients: What do we know? Respir Med 2016; 117: 122–130. https://doi.org/10.1016/j.rmed.2016.06.003 PMID: 27492522

12. Denollet J.K. Measurement of human muscle fatigue. J. Neurosci. Meth 1997; 74 (2): 219–227. https://doi.org/10.1016/s0165-0270(97)02251-6 PMID: 9219890

13. Cifrek M., Medved V., Tonković S., Ostojić S. Surface EMG based muscle fatigue evaluation in biomechanics. Clin biomech 2009; 24: 327–340. https://doi.org/10.1016/j.clinbiomech.2009.01.010 PMID: 19285766

14. Sheel A.W., Boushel R., Dempsey J.A. Competition for blood flow distribution between respiratory and locomotor muscles: implications for muscle fatigue. J Appl Physiol 2018; 125: 820–831. https://doi.org/10.1152/japplphysiol.00189.2018 PMID: 29878876

15. Dominelli P.B., Archiza B., Ramsook A.H., Mitchell R.A., Peters C.M., et al. Effects of respiratory muscle work on respiratory and locomotor blood flow during exercise. Exp Physiol 2017; 102. 11: 1535–1547. https://doi.org/10.1111/epj.13256 PMID: 28841267

16. Vogiatzis I., Athanasopoulos D., Habazettl H., Aliverti A., Louvaris Z., Cherouveim E., et al. Intercostal muscle blood flow limitation during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182: 1105–1113. https://doi.org/10.1164/rccm.201002-0172OC PMID: 20622032

17. American Thoracic Society/European Respiratory Society. ATS/ERS Statement on Respiratory Muscle Testing. Am J Respir Crit Care Med 2002; 166: 518–624. https://doi.org/10.1164/rccm.166.4.518 PMID: 12186331

18. Ertl P., Kruse A., Tilt M. Detecting fatigue thresholds from electromyographic signals: A systematic review on approaches and methodologies. J Electromyogr Kinesiol 2016; 30: 216–230 https://doi.org/10.1016/j.jelekin.2016.08.002 PMID: 27529668
20. Mortani T., Muro M. Motor unit activity and surface electromyogram power spectrum during increasing force of contraction. Eur J Appl Physiol. 1987; 56(3):260–5. https://doi.org/10.1007/BF00690890 PMID: 3569235

21. Basmajian J.V., De Luca C.J., 1985. Muscles Alive: Their Function Revealed by Electromyography, fifth ed. Williams and Wilkins, Baltimore.

22. Mills K.R. Power spectral analysis of electromyogram and compound muscle action potential during muscle fatigue and recovery. J. Physiol. 1982; 326: 401–409. https://doi.org/10.1113/jphysiol.1982.sp014201 PMID: 7108803

23. Allison G.T., Fujiwara T. The relationship between EMG median frequency and low frequency band amplitude changes at different levels of muscle capacity. Clin biomed (Bristol, Avon) 2002; 17: 464–469. https://doi.org/10.1016/s0268-0033(02)00033-5 PMID: 12135548

24. Spruit M.A., Singh S.J., Garvey C., ZuWallack R., Nici L., Rochester C., et al. American Thoracic Society/European Respiratory Society. As Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation. Am J Respir Crit Care Med 2013; 188 (8): e13–e64. https://doi.org/10.1164/rccm.201309-1634ST PMID: 24127811

25. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. American Thoracic Society/European Respiratory Society. Standardisation of spirometry. Eur Respir J 2005; 26: 319–338. https://doi.org/10.1183/09031936.05.00034805 PMID: 1605882

26. Pereira C.A.C., Sato T., Rodrigues S.C. Novos valores de referência para espirometria forçada em brasileiros adultos de raça branca. J Bras Pneumol 2007; 33(4): 397–406. https://doi.org/10.1590/s1806-37132007000400008 PMID: 17982531

27. Neder J.A., Andreoni S., Lerario M.C., Nery L.E. Reference values for lung function tests. II. Maximal respiratory pressures and voluntary ventilation. Braz J Med Biol Res 1999; 32(6): 719–727. https://doi.org/10.1590/s0100-879x1999000600007 PMID: 10412550

28. Araújo P.R.S., Resquei V.R., Nascimento J., Carvalho L.A., Cavalcanti A.G.L., Silva V.C., et al. Valores de referência da pressão inspiratória nasal em indivíduos saudáveis no Brasil: estudo multicêntrico. J Bras Pneumol 2012; 38 (6):700–707. https://doi.org/10.1590/s1806-37132012000600004 PMID: 23288114

29. Singh S.J., Morgan M.D.L., Scott S., Walters D., Hardman A.E. Development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992; 47: 1019–1024. https://doi.org/10.1136/thx.47.12.1019 PMID: 1494764

30. Jurgensen S.P., Antunes L.C.O., Tanni S.E., Banov M.C., Lucheta P.A., Bucceroni A.F., et al. The incremental shuttle walk test in older Brazilian adults. Respiration 2011; 81(3): 223–8. https://doi.org/10.1159/000319037 PMID: 20639622

31. Hermens H.J., Freriks B., Disselhorst-Klug C., Rau G. Development of recommendations for SEMG sensors and sensor placement procedures. J Electromyogr Kinesiol 2000; 10: 361–374. https://doi.org/10.1016/s1050-6411(00)00027-4 PMID: 11018445

32. Fallaa D., Dall’Alba P., Rainoldi A., Merletti R., Jull G. Location of innervation zones of sternoceiledomas-toid and scalene muscles--a basis for clinical and research electromyography applications. Clin Neurophysiol 2002; 113: 57–63. https://doi.org/10.1016/s1388-2457(01)00708-8 PMID: 11801425

33. Cunha A. P. N., Marinho P.E.M., Silva T.N.S., Francês E.E.T., Amorim C., Filho V.C.G., et al. Efeito do alongamento sobre a atividade dos músculos inspiratórios na DPOC. Saúde em Revista 2005; 7 (17): 13–19.

34. SENIAM- Surface ElectoMyoGraphy for the Non-Invasive Assessment of Muscles. [homepage from Internet]. Available in: http://www.seniam.org/

35. Ball N., Scurr J. Electromyography Normalization Methods for High-Velocity Muscle Actions: Review and Recommendations. J Appl Biomech 2013; 29. https://doi.org/10.1123/jab.29.5.600 PMID: 23270917

36. Camic C.L., Kovacs A.J., Enquist E.A., VanDusseldorp T.A., Hill E.C., Calantoni A.M., et al. An EMG frequency-based test for estimating the neuromuscular fatigue threshold during cycle ergometry. Eur J Appl Physiol 2010; 108: 337–34. https://doi.org/10.1007/s00421-009-1239-7 PMID: 19813019

37. Diefenthaler F., Bini F.F., Vaz M.A. Frequency band analysis of muscle activation during cycling to exhaustion. Rev Bras Cineantropom Desempenho Hum 2012; 14(3):243–253.

38. Cifrek M., Tonković S., Medved V. Measurement and analysis of surface myoelectric signals during fatigued cyclic dynamic contractions. Measurement 2000; 27: 85–92.

39. Aubier M., Farkas G., De Troyer A., Mozes R., Roussos C. Detection of diaphragmatic fatigue in man by phrenic stimulation. J Applied Physiol 1981; 50: 538–544.

40. Fritz C.O., Morris P.E., Richler J.J. Effect Size Estimates: Current Use, Calculations, and Interpretation. J Exper Psychol: Gen 2012; 141(1): 2–18.
41. Tomczak M., Tomczak E. The need to report effect size estimates revisited. An overview of some recommended measures of effect size. Trends Sport Sci 2014; 1(21): 19–25.

42. Martin J., Powell E., Shore S., Emrich J., Engel L. A. The role of respiratory muscles in the hyperinflation of bronchial asthma. Am. Rev. Respir. Dis. 1980; 121 (3): 441–447. https://doi.org/10.1164/arrd.1980.121.3.441 PMID: 7416577

43. Reilly C.C., Jolley C.J., Ward K., MacBean V., Moxham J., Rafferty G.F. Neural respiratory drive measured during inspiratory threshold loading and acute hypercapnia in healthy individuals. Exp Physiol 2013; 1190–1198. https://doi.org/10.1113/expphysiol.2012.071415 PMID: 23504646

44. Aliverti A. The respiratory muscles during Exercise. Breathe 2016 v.12, n. 2.

45. Konrad P. The ABC of EMG: A practical introduction to kinesiological electromyography 2006.

46. O’Donnell D.E., Revill S.M., Webb K.A. Dynamic Hyperinflation and Exercise Intolerance in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2001; 164: 770–777. https://doi.org/10.1164/ajrccm.164.5.2012122 PMID: 11549531

47. Johnson M.A., Polgar J., Weightman D., Appleton D. Data on the distribution of fibre types in thirty-six human muscles. An autopsy study. J Neurolog Sci 1973; 18: 111–129. https://doi.org/10.1016/0022-510X(73)90023-3 PMID: 4120482

48. Vikne H., Gundersen K., Liestøl K., Maelen J., Vøllestad N. Intermuscular relationship of human muscle fiber type proportions: slow leg muscles predict slow neck muscles. Muscle Nerve 2012; 45: 527–535. https://doi.org/10.1002/mus.22315 PMID: 22431086

49. Beck T.W., Stock M.S., Defreitas J.M. Shifts in emg spectral power during fatiguing dynamic contractions. AIChE J 2012. https://doi.org/10.1002/aic.12668 PMID: 23949093

50. Dempsey J.A., Sheel A.W., St Croix C.M., Morgan B.J. Respiratory influences on sympathetic vasomotor outflow in humans. Respir Physiol Neurobiol 2002; 130: 3–20. https://doi.org/10.1016/s0034-5687(01)00327-9 PMID: 12380012